Daiichi Sankyo's Q2 Revenue Surges 19.7% on Oncology Growth

Daiichi Sankyo’s revenue for the first half of fiscal year 2026 rose by 19.7% year-over-year to ¥1.1672 trillion, propelled by increased sales of its key oncology drugs, Enhertu and Datopotamab, and favorable exchange rate effects. Core operating profit jumped 46.9% to ¥2.213 trillion, demonstrating improved profitability despite increased costs.

The revenue increase was partially offset by higher selling, general, and administrative expenses due to increased profit-sharing with AstraZeneca, and a rise in research and development spending related to its 5DXd ADC and Next Wave portfolios. Despite these increased expenses, the company saw a 34.4% rise in operating profit to ¥1.938 trillion, although this was slightly reduced by one-time expenses related to a restructuring of its EU specialty business unit.

The company reaffirmed its previously announced full-year guidance, indicating sustained confidence in its growth trajectory. Daiichi Sankyo also announced an increased interim dividend, reflecting its positive financial performance. A noteworthy detail is the continued progress of its key development programs, including several ongoing Phase 3 trials for Enhertu and Datopotamab across various cancer types. The company is strategically expanding its oncology pipeline, with multiple potential new drug approvals anticipated in the coming years.

Daiichi Sankyo’s performance is unfolding against a backdrop of increasing demand for oncology treatments and a competitive landscape within the pharmaceutical industry. The company’s success in driving sales of its innovative therapies, combined with its strategic investments in research and development, positions it for continued growth in the oncology market. The company is also actively managing its cost structure and optimizing its operations to enhance profitability.

Overall, Daiichi Sankyo’s first-half results demonstrate a strong financial performance driven by its oncology portfolio. The company’s sustained revenue growth, improved profitability, and reaffirmed full-year guidance indicate a positive trajectory, while the increased interim dividend rewards shareholders and reflects management's confidence in the business.